Introduction

Diabetes significantly elevates the risk of developing vascular cognitive impairment and dementia. Recent research into the endothelin system in VCID highlights the critical link between vascular health and cognitive preservation. Specifically, scientists utilize microemboli (ME) models to demonstrate how diabetic conditions exacerbate white matter damage and accelerate cognitive decline. These studies offer vital insights into the mechanisms of brain tissue hypoxia and neuroinflammation.

The Impact of Microemboli and Hypoxia

The microemboli model reveals that diabetic rats experience more progressive cognitive deficits compared to healthy controls. Furthermore, these animals exhibit severe white matter damage following ME injection. This damage appears to stem from prolonged brain tissue hypoxia. Research indicates that brain endothelin-1 (bET-1) levels correlate directly with markers of tissue hypoxia in dementia patients. Consequently, understanding this relationship is essential for developing targeted interventions. While plasma ET-1 levels may remain stable, the localized activity within the brain environment drives significant pathological changes.

Therapeutic Modulation of the Endothelin System in VCID

Targeting vascular dysfunction before the onset of microembolic events may prevent the development of VCID. In recent experimental models, the administration of Isosorbide mononitrate (ISMN) and Cilostazol showed promising results. Specifically, this combination treatment reduced the expression of the endothelin A receptor (ETAR). Moreover, the therapy restored the expression of the endothelin B receptor (ETBR) to levels comparable to healthy controls. These findings suggest that modulating the endothelin system in VCID can effectively improve vascular integrity and reduce neuroinflammation. Therefore, restoring endothelial function serves as a viable therapeutic strategy to protect the aging diabetic brain.

Conclusion

The endothelin system acts as a pivotal mediator between diabetes-induced vascular dysfunction and cognitive deterioration. By addressing hypoxia and receptor expression, clinicians may find new ways to halt the progression of dementia in high-risk populations. Ongoing research continues to validate the use of vasodilators and anti-platelet agents in managing cerebral small vessel disease.

Frequently Asked Questions

How does diabetes contribute to VCID?

Diabetes causes early endothelial dysfunction and activates the endothelin system. This leads to reduced cerebral blood flow, brain tissue hypoxia, and increased sensitivity to microembolic injuries, ultimately causing cognitive decline.

What role does the endothelin system play in brain hypoxia?

The endothelin system, particularly ET-1, acts as a potent vasoconstrictor. High levels of brain ET-1 correlate with hypoxia markers, suggesting it regulates the vascular response to low oxygen levels and contributes to neuroinflammation.

Can medications like Cilostazol prevent cognitive decline?

Experimental evidence suggests that Cilostazol, often used with ISMN, can restore endothelial function and modulate ET receptor expression. This combined approach may prevent the white matter damage associated with vascular dementia.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Li W et al. Microemboli Model of Vascular Cognitive Impairment/Dementia (VCID) Presents with Long-term Brain Tissue Hypoxia: Relevance to the Endothelin (ET) System. Can J Physiol Pharmacol. 2026 Mar 04. doi: 10.1139/cjpp-2025-0350. PMID: 41780034.

Wardlaw JM et al. Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2). Lancet Neurol. 2023;22(5):395-407.

Ergul A et al. Endothelin and diabetic complications: a brain-centric view. nih.gov. 2018;133(1):1-10.